FTSE MIB
33.873,43 +244,22 (+0,73%) Dow Jones
38.855,52 +179,84 (+0,47%) Nasdaq
16.241,36 +85,03 (+0,53%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,55 +0,44 (+0,56%) Bitcoin EUR
59.180,90 -153,39 (-0,26%)
Comera Life Sciences Holdings, Inc. (CMRA)
- GlobeNewswire
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera,
- GlobeNewswire
Comera Life Sciences Announces the Completion of $4.1 Million Private Placement
WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares ar
- GlobeNewswire
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine’s Viscosity Reducing Capabilities
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmac
